GHK-Cu
₱2,400.00 Original price was: ₱2,400.00.₱1,900.00Current price is: ₱1,900.00.
Retatrutide
₱3,998.00 – ₱7,498.00Price range: ₱3,998.00 through ₱7,498.00
Tirzepatide
₱3,498.00 – ₱6,998.00Price range: ₱3,498.00 through ₱6,998.00
Tirzepatide is a dual GIP and GLP-1 receptor agonist—a new class of medication used primarily for type 2 diabetes and obesity. Here’s a comprehensive list of the benefits of Tirzepatide, based on current clinical data:
SKU:
N/A
Category: Slimming
Description
BENEFITS:
Powerful Weight Loss
- Average weight loss of 15–22%
- Appetite suppression and reduced cravings.
- Delayed gastric emptying
Blood Sugar Control (Type 2 Diabetes)
- Significantly lowers HbA1c levels.
- Helps restore insulin sensitivity.
- Improves fasting and post-meal glucose levels.
Cardiometabolic Health Improvements
- Improves cholesterol profiles: lowers LDL and triglycerides, increases HDL.
- Reduces blood pressure.
- Decreases inflammatory markers.
Preserves Lean Muscle Mass
- Unlike typical dieting, tirzepatide has shown better retention of muscle mass while losing fat.
Appetite and Behavior Regulation
- Acts on brain receptors to reduce food intake.
- Improves satiety signals and decreases emotional eating.
Possible Liver Health Benefits
- May improve non-alcoholic fatty liver disease
- Reduces liver fat and inflammation in early studies.
Low Risk of Hypoglycemia
- Especially when used without insulin or sulfonylureas.
- Because it’s glucose-dependent, it only activates insulin when needed.
Improved Quality of Life
- Increased energy, mobility, and confidence due to weight loss.
- Reduction in obesity-related conditions like sleep apnea, joint pain, and PCOS.
Additional information
| MG |
15mg ,30mg |
|---|
Reviews (0)
Be the first to review “Tirzepatide” Cancel reply
Shipping and Delivery
Related products
Retatrutide
₱3,998.00 – ₱7,498.00Price range: ₱3,998.00 through ₱7,498.00
Select options
This product has multiple variants. The options may be chosen on the product page
Retatrutide is an emerging triple hormone receptor agonist (GIP, GLP-1, and glucagon receptors), currently in clinical trials for treating obesity, type 2 diabetes, and metabolic disorders. It’s considered a next-generation weight loss drug—potentially more effective than both semaglutide and tirzepatide.

Reviews
There are no reviews yet.